30 November 2020 

The Russian Direct Investment Fund and pharma company Hetero have entered into an agreement to produce more than 100 million doses of Russia’s Sputnik V vaccine per year in India. The partners have agreed to start production of Sputnik V in 2021.

Colchicine, an anti-inflammatory drug used to treat gout, is due to be tested as a possible treatment for Covid-19 in one the world’s largest clinical trials, reports suggest. The University of Oxford-based RECOVERY trial will be conducted on hospitalised Covid-19 patients and will randomly allot approximately 2,500 patients to be administered with Colchicine.

Wayne State University (WSU) and John Hopkins University have collaborated to determine the potential benefits of convalescent blood plasma from Covid-19-infected donors on diagnosed and exposed individuals, as well as to understand if the antibodies can help fight the SARS-CoV-2 virus. The WSU researchers conducted outpatient clinical trials, which are being sponsored by the Johns Hopkins University.

Malaysia and pharma giant Pfizer have entered into an agreement for the supply of 12.8 million doses of Pfizer’s Covid-19 vaccine. This makes the Southeast Asian country the first to strike a deal with the US drug maker. Although Pfizer’s vaccine final trial data showed 95% effective, Asian countries are not betting on it due to the tropical climate, remote island communities and also the need for ultra-cold freezers in the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.